Sun Pharmaceutical Industries Inc.

Sun Pharmaceutical Industries Inc. is the U.S. subsidiary of Sun Pharmaceutical Industries Ltd., an Indian multinational pharmaceutical company. The parent company was founded in 1983 by Dilip Shanghvi and is headquartered in Mumbai, India. Sun Pharmaceutical Industries Inc. maintains its U.S. headquarters in Princeton, New Jersey. The global enterprise is publicly traded, with its founding family holding a majority stake. Globally, Sun Pharmaceutical Industries employs over 43,000 people and reported annual revenues exceeding $6 billion as of fiscal years 2024-2026. The U.S. market contributes approximately one-third of these global revenues.

As a leading global pharmaceutical company, Sun Pharma manufactures and sells a diverse portfolio of pharmaceutical formulations and active pharmaceutical ingredients (APIs) across more than 100 countries. Their offerings include innovative medicines, generics, branded generics, specialty products, and over-the-counter (OTC) medications. Key therapeutic areas span dermatology, ophthalmology, cardiology, neurology, and oncology, with notable products such as Ilumya for plaque psoriasis, Absorica for severe acne, and Cequa for dry eye disease.

Sun Pharmaceutical Industries Inc. demonstrates an active patent-litigation posture, focused on asserting and defending its intellectual property. The company is recorded as a plaintiff in one tracked case at the Patent Trial and Appeal Board (PTAB) and has no defendant cases in the provided data. This PTAB case, Sun Pharmaceutical Industries Inc. v. Biofrontera Bioscience GmbH, is an Inter Partes Review (IPR) initiated by Biofrontera to challenge Sun Pharma's patent.

This specific PTAB action stems from Sun Pharma's earlier patent infringement allegations against Biofrontera, filed in June 2024 in a U.S. District Court and the International Trade Commission, concerning U.S. Patent No. 11,697,028 and a related patent. On February 23, 2026, the PTAB issued a Final Written Decision in the tracked case, finding all challenged claims of Sun Pharma's U.S. Patent No. 11,697,028 to be unpatentable, though Sun Pharma retains the right to appeal this decision.